Bioequivalence in Japan [Regulatives / Guidelines]

posted by mangurohit – India, 2010-02-03 06:21 (4796 d 11:48 ago) – Posting: # 4697
Views: 3,570

Dear Friends,

Hope this mail finds you in pink of your health and spirit.

Further to the response to my query about the approval of generic drug in Japan necessiates Japanese population only, I would like to know than what are the different ethnic factors (or other factors) that differenciate japanese population from others (e.g. Indian Population)?

Kindly provide the reasons (Provided by regulatory body) if you have, why only Japanese population is required for the bioequivalence study, for the approval in Japan market?

According to ICH E5, Is it not applicable to apply foreign clinical data in Japan?

Hope for the quick response.
Mangu Rohit

Edit: Linked to previous thread; see the Policy. [Helmut]

Complete thread:

UA Flag
 Admin contact
22,548 posts in 4,723 threads, 1,606 registered users;
25 visitors (0 registered, 25 guests [including 10 identified bots]).
Forum time: 18:09 CET (Europe/Vienna)

You can’t really say “similar” if it’s the same again you want.
“Similar” means something different.    Anthony Burgess

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz